Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032

Business Upturn

07-05-2025

By GlobeNewswire Published on May 7, 2025, 22:00 IST
New York, USA, May 07, 2025 (GLOBE NEWSWIRE) — Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight
The demand for AI in clinical trials is experiencing strong growth, primarily fueled by the rising global prevalence of chronic illnesses like diabetes, cardiovascular diseases, respiratory conditions, and cancer. This growth is further bolstered by increasing investments and funding dedicated to enhancing drug discovery and development. Additionally, the expanding trend of strategic alliances and partnerships among pharmaceutical, biotechnology, and medical device firms is significantly contributing to the accelerated adoption of AI-driven clinical trial technologies.
DelveInsight's AI in Clinical Trials Market Insights report provides the current and forecast market analysis, individual leading AI in clinical trials companies' market shares, challenges, AI in clinical trials market drivers, barriers, trends, and key market AI in clinical trials companies in the market.
Key Takeaways from the AI in Clinical Trials Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in clinical trials market during the forecast period.
In the product segment of the AI in clinical trials market, the software category had a significant revenue share in 2024.
Notable AI in clinical trials companies such as TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and several others are currently operating in the AI in clinical trials market.
and several others are currently operating in the AI in clinical trials market. In March 2025, Suvoda launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle.
launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle. In December 2024, ConcertAI and NeoGenomics announced the launch of CTO-H, a next-generation AI software solution for research analytics, clinical trial design, and operational optimization. CTO-H delivers an unparalleled research data platform, offering unmatched scale, longitudinal patient insights, and deep biomarker data, enabling more precise, efficient, and data-driven clinical development strategies.
announced the launch of CTO-H, a next-generation AI software solution for research analytics, clinical trial design, and operational optimization. CTO-H delivers an unparalleled research data platform, offering unmatched scale, longitudinal patient insights, and deep biomarker data, enabling more precise, efficient, and data-driven clinical development strategies. In June 2024, Lokavant launched Spectrum™, the first AI-driven clinical trial feasibility solution designed to optimize trial performance across the entire clinical development value chain. Spectrum empowers study teams to predict, manage, and optimize trial timelines and costs in real-time.
To read more about the latest highlights related to the AI in clinical trials market, get a snapshot of the key highlights entailed in the Global AI in Clinical Trials Market Report
AI in Clinical Trials Overview
Artificial intelligence (AI) is revolutionizing clinical trials by enhancing efficiency, accuracy, and patient outcomes across the entire trial lifecycle. AI-powered tools enable faster patient recruitment by analyzing electronic health records and identifying eligible candidates based on complex inclusion and exclusion criteria. This targeted approach reduces trial enrollment time and improves diversity among participants. Additionally, AI can optimize trial design by simulating outcomes using real-world data, allowing researchers to refine protocols and predict potential risks, ultimately leading to more robust and reliable results.
Moreover, AI facilitates real-time monitoring and data analysis during trials, enabling early detection of adverse events and anomalies. Machine learning algorithms can process vast amounts of data from wearable devices, lab results, and patient-reported outcomes to identify patterns that might be overlooked by traditional methods. This enhances decision-making and allows for adaptive trial designs, where protocols can be modified in response to interim findings. As regulatory bodies grow more comfortable with AI-driven methodologies, the integration of AI in clinical trials holds the promise of accelerating drug development while ensuring safety and efficacy.
AI in Clinical Trials Market Insights
North America held the largest share of the AI in clinical trials market in 2024. This leading position is driven by several key factors, including the increasing burden of chronic diseases, substantial R&D investments, and a growing volume of clinical trials in the region. The market is also benefiting from the rise in research collaborations and strategic partnerships among pharmaceutical and medical device companies, alongside the continuous development of sophisticated AI technologies.
Major players in the North American market are making significant R&D investments to develop cutting-edge AI tools aimed at streamlining clinical trials. For instance, in October 2022, Phesi introduced its AI-driven Trial Accelerator platform, which enhances clinical trial planning through real-time scenario analysis. Utilizing the world's most comprehensive clinical trial database, this SaaS platform helps optimize patient recruitment, endpoint determination, country selection, and site allocation—boosting trial efficiency and outcomes.
Likewise, in October 2023, H1 launched GenosAI, a generative AI feature integrated into its Trial Landscape platform. GenosAI is designed to improve clinical trial decision-making by enabling pharmaceutical companies to analyze complex data, simplify trial-related queries, and expedite the selection of sites and principal investigators, thereby facilitating quicker and more strategic trial initiations.
As a result, these factors are expected to drive substantial growth in the North American AI in clinical trials market throughout the 2025–2032 forecast period.
To know more about why North America is leading the market growth in the AI in clinical trials market, get a snapshot of the AI in Clinical Trials Market Outlook
AI in Clinical Trials Market Dynamics
The AI in clinical trials market is experiencing significant growth, driven by advancements in artificial intelligence, machine learning, and data analytics. AI technologies are being increasingly adopted to streamline clinical trial processes, such as patient recruitment, data collection, and monitoring. AI-powered tools help researchers identify suitable candidates faster, reducing the time and costs associated with recruitment. Additionally, AI aids in personalized treatment regimens by analyzing large datasets to identify optimal patient profiles and predict outcomes more accurately.
One of the major factors fueling the market's growth is the need for improving efficiency in clinical trials. AI facilitates real-time monitoring of patient health, enabling researchers to detect potential issues early and make data-driven decisions. By automating time-consuming tasks, AI reduces human error, improves trial design, and accelerates the pace of development for new therapies. This increased efficiency is especially critical as the pharmaceutical industry faces growing pressure to bring drugs to market quickly due to competitive pressures and a rising demand for novel treatments.
Another key driver in the AI in clinical trials market is the increasing complexity of modern drug development. With more targeted therapies, such as immunotherapies and gene therapies, clinical trials require sophisticated designs to accommodate diverse patient populations and intricate treatment regimens. AI technologies, including predictive analytics and natural language processing, help streamline this complexity by analyzing vast datasets to uncover meaningful insights. This supports the creation of more robust trial designs and accelerates decision-making processes, ultimately reducing costs.
Despite its advantages, the adoption of AI in clinical trials faces challenges, such as concerns around data privacy, regulatory compliance, and the need for skilled personnel. Healthcare data is highly sensitive, and regulatory bodies are still adapting to ensure AI tools meet the necessary standards for clinical use. Furthermore, while AI can greatly assist in data analysis, the technology still requires human oversight to interpret results and ensure that ethical guidelines are followed. Addressing these challenges will be crucial for widespread AI adoption and for realizing its full potential in clinical trials.
Looking ahead, the AI in clinical trials market is expected to expand further with the integration of more advanced AI capabilities, including deep learning and real-time data integration from wearables and remote monitoring devices. As healthcare systems continue to digitize and AI technologies evolve, their use in clinical trials will likely become more ubiquitous, making trials faster, cheaper, and more effective. The market is poised for continued growth, with AI playing a pivotal role in shaping the future of clinical research.
Get a sneak peek at the AI in clinical trials market dynamics @ AI in Clinical Trials Market Dynamics Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Clinical Trials Market CAGR ~12% AI in Clinical Trials Market Size by 2032 USD 3.3 Billion Key AI in Clinical Trials Companies TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others
AI in Clinical Trials Market Assessment AI in Clinical Trials Market Segmentation AI in Clinical Trials Market Segmentation By Product: Software and Services AI in Clinical Trials Market Segmentation By Technology: Machine Learning (ML), Natural Language Processing (NLP), and Others AI in Clinical Trials Market Segmentation By Application: Clinical Trial Design & Optimization, Patient Identification & Recruitment, Site Identification & Trial Monitoring, and Others AI in Clinical Trials Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others AI in Clinical Trials Market Segmentation By End-User: Pharmaceutical & Biotechnology Companies and Medical Device Companies AI in Clinical Trials Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the AI in clinical trials market are set to emerge as the trendsetter explore @ AI in Clinical Trials Companies
Table of Contents 1 AI in Clinical Trials Market Report Introduction 2 AI in Clinical Trials Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Clinical Trials Market Key Factors Analysis 6 AI in Clinical Trials Market Porter's Five Forces Analysis 7 AI in Clinical Trials Market Layout 8 AI in Clinical Trials Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us
Interested in knowing the AI in clinical trials market by 2032? Click to get a snapshot of the AI in Clinical Trials Market Trends
Related Reports
Artificial Intelligence in Drug Commercialization Market
Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others.
Artificial Intelligence in Precision Medicine Market
Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others.
Artificial Intelligence In Drug Discovery Market
Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others.
Artificial Intelligence in Medical Imaging Market
Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others.
Artificial Intelligence in Life Sciences Market
Artificial Intelligence in Life Sciences Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in life sciences companies, including IBM Corporation, Atomwise, Inc., Nuance Communications, Inc., NuMedii, Inc., AiCure LLC, APIXIO, Inc., Insilico Medicine, Inc., Enlitic, Inc., Sensely, Inc., Zebra Medical Vision, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.